Cargando…
Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey
Objectives The aim of the European REVIVE survey was to achieve a better understanding of vulvovaginal atrophy (VVA), a chronic and progressive condition after menopause. We investigated perceptions, experiences and needs in terms of sexual and vaginal health in a sample of European postmenopausal w...
Autores principales: | Nappi, R. E., Palacios, S., Panay, N., Particco, M., Krychman, M. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819825/ https://www.ncbi.nlm.nih.gov/pubmed/26581580 http://dx.doi.org/10.3109/13697137.2015.1107039 |
Ejemplares similares
-
Management of Vaginal Atrophy: Implications from the REVIVE Survey
por: Wysocki, Susan, et al.
Publicado: (2014) -
The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy
por: Nappi, R. E., et al.
Publicado: (2015) -
Ospemifene for vulvar and vaginal atrophy: an overview
por: Palacios, Santiago
Publicado: (2020) -
WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history
por: Kingsberg, Sheryl A., et al.
Publicado: (2019) -
Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy
por: Bruyniks, N., et al.
Publicado: (2016)